2015 was a pivotal year for Ethypharm as it moved away from using partners for the commercialisation of its morphine range and began selling directly into France and the UK. In addition, Ethypharm transferred to China the manufacturing of its leading local product. By adding sales & marketing to its range of activities, the foundations of a specialty pharmaceutical company were laid.
Since then the Group has increased its footprint to full coverage of the top 5 European markets, in order to be ever closer to patients and health care providers.
Ethypharm launched its affiliate in Germany in 2016 and in 2017 acquired Martindale Pharma, a leading UK-based specialty pharmaceutical company focused on opioid dependency, critical care and sterile injectables. In 2021, Ethypharm established an affiliate to operate directly in Italy, the third-largest pharmaceutical market in Europe, and acquired Altan Pharma, thereby entering the Spanish market and enhancing its portfolio of Hospital Injectable products and R&D pipeline.